Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores An Analysis of Mortality and Morbidity in PARADIGM-HF

ConclusionsAlthough most PARADIGM-HF patients had mild symptoms, many were at high risk for adverse outcomes and obtained a large absolute benefit from LCZ696, compared with enalapril, over a relatively short treatment period. LCZ696’s benefit was consistent across the spectrum of risk. (PARADIGM-HF trial [Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure]; NCT01035255)

http://Content.onlinejacc.org/article.aspx?articleID=2468523

Source: Journal of the American College of Cardiology - November 2, 2015 Category: Cardiology Source Type: research